Quality Systems – Page 87

OOS investigation lacks root cause in stability testing – improving right-first-time testing metrics

Improving Right-First-Time Testing Metrics in OOS Investigations for Stability Testing Investigating out-of-specification (OOS) results from stability testing poses a significant challenge in pharmaceutical quality control. These investigations often reveal complex…

Inadequate risk assessment during regulatory inspection readiness – regulatory expectation gap and how to fix it

Addressing Gaps in Risk Assessment for Regulatory Inspections: Practical Solutions Pharmaceutical manufacturing faces complex challenges, especially regarding regulatory inspections. Instances of inadequate risk assessment during preparation can lead to significant…

Quality event trending ignored during internal audit follow-up – how to prevent repeat observations

Addressing Trends in Quality Events Ignored During Internal Audits to Prevent Recurrences In pharmaceutical manufacturing, quality assurance (QA) is paramount, and internal audits are a critical component of maintaining compliance…

Inconsistent SOP interpretation during complaint triage – GDP documentation do’s and don’ts

Addressing the Challenges of SOP Interpretation During Complaint Triage in Pharma Operations In the dynamic environment of pharmaceutical manufacturing, the adherence to Standard Operating Procedures (SOPs) is crucial for ensuring…

Batch disposition delayed during change control governance – how to prevent repeat observations

Addressing Delays in Batch Disposition During Change Control Governance In the fast-paced environment of pharmaceutical manufacturing, delays in batch disposition can have significant ramifications beyond mere operational efficiency. Such delays…

Batch disposition delayed during QA review – risk-based justification template for decisions

Addressing Delays in Batch Disposition During Quality Assurance Review Delays in batch disposition during the Quality Assurance (QA) review process can have significant implications for pharmaceutical operations. These delays may…

Inconsistent SOP interpretation during management review – risk-based justification template for decisions

Addressing Inconsistent SOP Interpretations during Management Reviews in Pharma Operations Inconsistent Standard Operating Procedure (SOP) interpretations during management reviews can lead to significant operational risks, affecting product quality and compliance…

Supplier deviation not assessed during complaint triage – CAPA effectiveness verification framework

Assessing Supplier Deviations During Complaint Triage: A Framework for CAPA Effectiveness Verification In pharmaceutical manufacturing, the integrity of raw materials and components is crucial to ensuring product quality and compliance.…

Inconsistent SOP interpretation during management review – regulatory expectation gap and how to fix it

Addressing Inconsistent Interpretation of SOPs in Management Reviews: A Pragmatic Investigation Approach In pharmaceutical operations, the consistent interpretation of Standard Operating Procedures (SOPs) is critical for ensuring compliance and maintaining…

CAPA overdue beyond target date during batch release decision – GDP documentation do’s and don’ts

Addressing CAPA Delays Beyond Target Dates During Batch Release Decision In pharmaceutical manufacturing, a timely corrective and preventive action (CAPA) process is critical to ensuring compliance with Good Manufacturing Practices…

Deviation closed without effectiveness check during internal audit follow-up – regulatory expectation gap and how to fix it

Closing Deviations Without Effectiveness Checks: Bridging the Regulatory Gap In a structured pharmaceutical manufacturing environment, the adherence to Good Manufacturing Practices (GMP) is fundamental to ensuring product quality and compliance.…

Training evidence weak during batch release decision – FDA/MHRA inspector questions to prepare for

How to Address Weak Training Evidence During Batch Release Decisions in Pharma Operations In the highly regulated pharmaceutical industry, robust training documentation is essential, especially during batch release decision-making. When…